1. Home
  2. LQDA vs ATEN Comparison

LQDA vs ATEN Comparison

Compare LQDA & ATEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • ATEN
  • Stock Information
  • Founded
  • LQDA 2004
  • ATEN 2004
  • Country
  • LQDA United States
  • ATEN United States
  • Employees
  • LQDA N/A
  • ATEN N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • ATEN EDP Services
  • Sector
  • LQDA Health Care
  • ATEN Technology
  • Exchange
  • LQDA Nasdaq
  • ATEN Nasdaq
  • Market Cap
  • LQDA 1.3B
  • ATEN 1.3B
  • IPO Year
  • LQDA 2018
  • ATEN 2014
  • Fundamental
  • Price
  • LQDA $13.17
  • ATEN $17.78
  • Analyst Decision
  • LQDA Strong Buy
  • ATEN Buy
  • Analyst Count
  • LQDA 9
  • ATEN 2
  • Target Price
  • LQDA $27.67
  • ATEN $21.00
  • AVG Volume (30 Days)
  • LQDA 3.0M
  • ATEN 595.1K
  • Earning Date
  • LQDA 08-06-2025
  • ATEN 07-29-2025
  • Dividend Yield
  • LQDA N/A
  • ATEN 1.35%
  • EPS Growth
  • LQDA N/A
  • ATEN 9.85
  • EPS
  • LQDA N/A
  • ATEN 0.67
  • Revenue
  • LQDA $14,144,000.00
  • ATEN $267,158,000.00
  • Revenue This Year
  • LQDA $185.38
  • ATEN $9.40
  • Revenue Next Year
  • LQDA $350.95
  • ATEN $7.66
  • P/E Ratio
  • LQDA N/A
  • ATEN $26.47
  • Revenue Growth
  • LQDA N/A
  • ATEN 4.90
  • 52 Week Low
  • LQDA $8.26
  • ATEN $12.27
  • 52 Week High
  • LQDA $19.41
  • ATEN $21.90
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 36.80
  • ATEN 52.36
  • Support Level
  • LQDA $13.60
  • ATEN $17.64
  • Resistance Level
  • LQDA $14.63
  • ATEN $18.48
  • Average True Range (ATR)
  • LQDA 0.96
  • ATEN 0.40
  • MACD
  • LQDA -0.40
  • ATEN -0.02
  • Stochastic Oscillator
  • LQDA 0.46
  • ATEN 46.99

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

Share on Social Networks: